Hypogonadism: a neglected comorbidity in ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Hypogonadism: a neglected comorbidity in young and middle-aged HIV-positive men on effective cART.
Author(s) :
Lachâtre, Marie [Auteur]
CIC Cochin Pasteur [CIC 1417]
Pasquet, Armelle [Auteur]
SAMU 75 [Paris]
Centre Hospitalier de Tourcoing
Ajana, Faïza [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Soudan, Benoit [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Quertainmont, Yann [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Lion, Georges [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Durand, Emmanuel [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Bocket, Laurence [Auteur]
Pathogenèse virale du diabète de type 1 - ULR 3610
Mole, Martine [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Cornavin, Pauline [Auteur]
Centre Hospitalier de Tourcoing
Catalan, Pilartxo [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Senneville, Eric [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Goujard, Cécile [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Boufassa, Faroudy [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Chéret, Antoine [Auteur]
Rétrovirus, Quiescence et Prolifération
Institut Cochin [IC UM3 (UMR 8104 / U1016)]
CIC Cochin Pasteur [CIC 1417]
Pasquet, Armelle [Auteur]
SAMU 75 [Paris]
Centre Hospitalier de Tourcoing
Ajana, Faïza [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Soudan, Benoit [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Quertainmont, Yann [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Lion, Georges [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Durand, Emmanuel [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Bocket, Laurence [Auteur]
Pathogenèse virale du diabète de type 1 - ULR 3610
Mole, Martine [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Cornavin, Pauline [Auteur]
Centre Hospitalier de Tourcoing
Catalan, Pilartxo [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Senneville, Eric [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Goujard, Cécile [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Boufassa, Faroudy [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Chéret, Antoine [Auteur]
Rétrovirus, Quiescence et Prolifération
Institut Cochin [IC UM3 (UMR 8104 / U1016)]
Journal title :
AIDS
Abbreviated title :
AIDS
Volume number :
36
Pages :
1061-1071
Publication date :
2022-02-05
ISSN :
1473-5571
English keyword(s) :
antiretroviral therapy
free testosterone
HIV
hypogonadism
testosterone
free testosterone
HIV
hypogonadism
testosterone
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objective:
Male hypogonadism is poorly characterized in young-to-middle-aged people with HIV (PWH). We used a reliable free testosterone assay to assess the prevalence and predictive factors for male hypogonadism in ...
Show more >Objective: Male hypogonadism is poorly characterized in young-to-middle-aged people with HIV (PWH). We used a reliable free testosterone assay to assess the prevalence and predictive factors for male hypogonadism in PWH on effective combined antiretroviral therapy (cART). Design: A French cross-sectional study from January 2013 to June 2016. Methods: We included HIV-1-infected men aged between 18 and 50years with HIV loads of 50 RNA copies/ml or less, on effective cART for at least 6 months. Hypogonadism was defined, according to guidelines, as a mean calculated serum free testosterone concentration less than 70pg/ml (Vermeulen equation). Sociodemographic, anthropo-metric, bone-densitometry, hormonal, immunovirological, metabolic, and therapeutic parameters were collected. The IIEF-5, HAM-D, and AMS scales, respectively, assessed erectile function, depression, and quality of life. Results: Overall, 240 patients were enrolled, 231 were analyzed. Low free testosterone concentrations (<70pg/ml) were recorded in 20 patients (8.7%), and were exclusively of secondary origin. In multivariable analysis, the risk factors predictive of male hypogonadism were age more than 43 years [adjusted odds ratio (aOR) 3.17, 95% confidence interval (95% CI) 1.02–9.86;P = 0.04], total fat percentage more than 19% (aOR3.5, 95% CI 1.18–10.37; P = 0.02), and treatment including efavirenz (aOR3.77, 95% CI 1.29–10.98;P = 0.02). A nadir CD4+ T-cell count more than 200 cells/μl (aOR 0.22, 95% CI 0.07–0.65;P < 0.01) were protective. Conclusion: Male hypogonadism remains common in young-to-middle-aged PWH with stably suppressed viral replication. Treatment including efavirenz, being over 43 years old, and having a total body fat percentage greater than 19% could be used as criteria for identifying PWH at risk. Early screening for male hypogonadism might improve care by identifying patients requiring testosterone replacement.Show less >
Show more >Objective: Male hypogonadism is poorly characterized in young-to-middle-aged people with HIV (PWH). We used a reliable free testosterone assay to assess the prevalence and predictive factors for male hypogonadism in PWH on effective combined antiretroviral therapy (cART). Design: A French cross-sectional study from January 2013 to June 2016. Methods: We included HIV-1-infected men aged between 18 and 50years with HIV loads of 50 RNA copies/ml or less, on effective cART for at least 6 months. Hypogonadism was defined, according to guidelines, as a mean calculated serum free testosterone concentration less than 70pg/ml (Vermeulen equation). Sociodemographic, anthropo-metric, bone-densitometry, hormonal, immunovirological, metabolic, and therapeutic parameters were collected. The IIEF-5, HAM-D, and AMS scales, respectively, assessed erectile function, depression, and quality of life. Results: Overall, 240 patients were enrolled, 231 were analyzed. Low free testosterone concentrations (<70pg/ml) were recorded in 20 patients (8.7%), and were exclusively of secondary origin. In multivariable analysis, the risk factors predictive of male hypogonadism were age more than 43 years [adjusted odds ratio (aOR) 3.17, 95% confidence interval (95% CI) 1.02–9.86;P = 0.04], total fat percentage more than 19% (aOR3.5, 95% CI 1.18–10.37; P = 0.02), and treatment including efavirenz (aOR3.77, 95% CI 1.29–10.98;P = 0.02). A nadir CD4+ T-cell count more than 200 cells/μl (aOR 0.22, 95% CI 0.07–0.65;P < 0.01) were protective. Conclusion: Male hypogonadism remains common in young-to-middle-aged PWH with stably suppressed viral replication. Treatment including efavirenz, being over 43 years old, and having a total body fat percentage greater than 19% could be used as criteria for identifying PWH at risk. Early screening for male hypogonadism might improve care by identifying patients requiring testosterone replacement.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Submission date :
2023-11-15T05:02:38Z
2024-05-13T07:14:30Z
2024-05-13T07:14:30Z
Files
- hypogonadism__a_neglected_comorbidity_in_young_and.2.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States